GILLIS JONATHAN 4

What Happened

• Jonathan Gillis, Chief Accounting & Administrative Officer (CAAO) and Principal Accounting Officer (PAO) of MapLight Therapeutics (MPLT), received equity awards on 2026-02-05: 6,020 shares (RSU award) and 24,455 derivative units, all at $0.00 per share — total 30,475 award units. These were grants/awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-05; filing date: 2026-02-09 (filed within the standard Form 4 reporting window).
• Price: $0.00 per share (no cash paid).
• Total awarded: 6,020 RSUs + 24,455 derivative units = 30,475 units.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes from the filing:
  • F1: The RSU award vests 1/4 on Jan 1, 2027, then 1/16th on each subsequent Apr 1, Jul 1, Oct 1 and Jan 1, subject to continued service.
  • F2: Each RSU represents a contingent right to receive one share of common stock.
  • F3: A separate award/derivative has an option‑style vesting schedule: 1/4 vests on Feb 5, 2027, then 1/48th vests monthly thereafter, subject to continued service.
• No 10b5-1 plan, tax withholding, or immediate sale/exercise was reported in the provided details.

Context

• RSUs and similar derivative awards are compensation that convert to shares only as they vest; they do not represent an immediate cash investment by the insider. Such grants are common for employee retention and do not necessarily signal buying or selling intent. The larger 24,455-unit award appears structured with a monthly vesting schedule (per F3), while the 6,020-unit award follows multi-quarter vesting (per F1/F2).